会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Viral polymerase inhibitors
    • 病毒聚合酶抑制剂
    • US07576079B2
    • 2009-08-18
    • US11333163
    • 2006-01-17
    • Pierre Louis BeaulieuGulrez FazalSylvie GouletGeorge KukoljMartin PoirierYoula S. TsantrizosJames GillardMarc-Andre Poupart
    • Pierre Louis BeaulieuGulrez FazalSylvie GouletGeorge KukoljMartin PoirierYoula S. TsantrizosJames GillardMarc-Andre Poupart
    • A61K31/5377A61K31/454C07D417/14
    • C07D333/62C07D209/08C07D209/30C07D209/42C07D401/04C07D403/04C07D405/04C07D409/04C07D413/04C07D417/04C07D471/04
    • An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein: A is O, S, NR1, or CR1, wherein R1 is defined herein;  represents either a single or a double bond; R2 is selected from 6 or 10-membered aryl and Het, each optionally substituted with R20; provided that Het is not a 5- or 6-membered monocyclic heterocycle having 1 or 2 nitrogen heteroatoms; B is NR3 or CR3, with the proviso that one of A or B is either CR1 or CR3, wherein R3 is defined herein; K is N or CR4, wherein R4 is defined herein; L is N or CR5, wherein R5 has the same definition as R4; M is N or CR7, wherein R7 has the same definition as R4; Y1 is O or S; Z is N(R6a)R6 or OR6, wherein R6a is H or alkyl or NR61R62 wherein R61 and R62 are defined herein; and R6 is H, alkyl, cycloalkyl, alkenyl, Het, alkyl-aryl, alkyl-Het; or R6 is wherein R7 and R8 and Q are as defined herein; Y2 is O or S; R9 is H, (C1-6 alkyl), (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl, aryl, Het, (C1-6)alkyl-aryl or (C1-6)alkyl-Het, all of which optionally substituted with R90; or R9 is covalently bonded to either of R7 or R8 to form a 5- or 6-membered heterocycle; a salt or a derivative thereof, as an inhibitor of HCV NS5B polymerase.
    • 由式I表示的化合物的异构体,对映体,非对映异构体或互变异构体:其中:A是O,S,NR1或CR1,其中R1如本文所定义; “img id =”CUSTOM-CHARACTER-00001“he =”2.46mm“wi =”6.35mm“file =”US07576079-20090818-P00001.TIF“alt =”custom character“img-content =”character“img-format =“tif”/>表示单键或双键; R2选自6或10元芳基和Het,各自任选被R 20取代; 条件是Het不是具有1或2个氮杂原子的5或6元单环杂环; B是NR 3或CR 3,条件是A或B中的一个是CR 1或CR 3,其中R 3在本文中定义; K是N或CR 4,其中R 4在本文中定义; L是N或CR5,其中R5与R4具有相同的定义; M是N或CR7,其中R7与R4具有相同的定义; Y1为O或S; Z是N(R6a)R6或OR6,其中R6a是H或烷基或NR61R62,其中R61和R62在本文中定义; 且R 6为H,烷基,环烷基,烯基,Het,烷基 - 芳基,烷基-Het; 或R6是其中R7和R8和Q如本文所定义; Y2为O或S; R9是H,(C1-6烷基),(C3-7)环烷基或(C1-6)烷基 - (C3-7)环烷基,芳基,Het,(C1-6)烷基 - 芳基或(C1-6) 烷基-Het,它们全部被R90取代; 或R 9与R 7或R 8中的任一个共价连接以形成5-或6-元杂环; 其盐或其衍生物,作为HCV NS5B聚合酶的抑制剂。
    • 5. 发明授权
    • Viral polymerase inhibitors
    • 病毒聚合酶抑制剂
    • US06841566B2
    • 2005-01-11
    • US10198259
    • 2002-07-18
    • Pierre Louis BeaulieuGulrez FazalSylvie GouletGeorge KukoljMartin PoirierYoula S. Tsantrizos
    • Pierre Louis BeaulieuGulrez FazalSylvie GouletGeorge KukoljMartin PoirierYoula S. Tsantrizos
    • A61K31/13A61K31/4184A61K31/427A61K31/428A61K31/437A61K31/4439A61K31/454A61K31/506A61K31/5377A61K31/7056A61K38/21A61K38/43A61K45/00A61P31/12A61P31/22A61P43/00C07D235/18C07D401/04C07D401/12C07D403/04C07D405/04C07D405/14C07D409/04C07D409/14C07D417/14C07D471/04C07D495/04C07H19/056
    • C07D401/04C07D235/18C07D403/04C07D405/04C07D405/14C07D409/04C07D409/14C07D417/14C07D471/04
    • An isomer, enantiomer, diastereoisomer, or tautomer of a compound, represented by formula I: wherein R1 is selected from: H, haloalkyl, (C1-6)alkyl, (C2-6)alkenyl, (C3-7)cycloalkyl, (C2-6)alkynyl, (C5-7)cycloalkenyl, 6 or 10-membered aryl, Het all optionally substituted; R2 is selected from (C1-6)alkyl, (C3-7)cycloalkyl, (C6-10)bicycloalkyl, 6- or 10-membered aryl, or Het all optionally substituted; B is N or CR5, wherein R5 is H, halogen, haloalkyl, (C1-6)alkyl, (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl; X is N or CR5; D is N or CR5; each of Y1 and Y2 is independently O or S; Z is O, N, or NRZ wherein RZ is H, (C1-6)alkyl, (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl; R3 and R4 are each independently H, (C1-6)alkyl, first (C3-7)cycloalkyl or 6- or 10-membered aryl, Het (C1-6)alkyl-6- or 10-membered aryl, (C1-6)alkyl-Het; or each R3 and R4 are independently covalently bonded together to form second (C3-7)cycloalkyl, or heterocycle, all optionally substituted; or when Z is N, either R3 or R4 are independently covalently bonded thereto to form a nitrogen-containing heterocycle; R7 is H, (C1-6alkyl), (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl; or R7 is covalently bonded to either of R3 or R4 to form a heterocycle; A is (C1-6)alkyl-CONHR8 wherein R8 is -6- or 10-membered aryl, or Het; or A is a 6- or 10-membered aryl, or Het said aryl or Het being optionally substituted; or a salt or a derivative thereof; such compounds being potent inhibitors of HCV NS5B polymerase.
    • 由式I表示的化合物的异构体,对映异构体,非对映异构体或互变异构体:其中R 1选自:H,卤代烷基,(C 1-6)烷基,(C 2-6)烯基,(C 3-7) 环烷基,(C 2-6)炔基,(C 5-7)环烯基,6或10元芳基,Het全部被取代; R 2选自(C 1-6)烷基,(C 3-7)环烷基,( C 6-10)双环烷基,6-或10-元芳基,或任意取代的Het; B为N或CR 5,其中R 5为H,卤素,卤代烷基,(C 1-6)烷基,(C 3 -7)环烷基或(C 1-6)烷基 - (C 3-7)环烷基; X为N或CR <5>; D为N或CR 5; Y1和Y2各自独立地为O或S; Z是O,N或NR Z,其中R Z是H,(C 1-6)烷基,(C 3-7)环烷基或(C 1-6)烷基 - (C 3-7)环烷基; R 3和R 4各自独立地为H,(C 1-6)烷基,第一(C 3-7)环烷基或6-或10-元芳基,Het(C 1-6)烷基-6-或10- (C 1-6)烷基-Het; 或每个R 3和R 4独立地共价键合在一起形成全部任意取代的第二(C 3-7)环烷基或杂环; 或当Z为N时,R 3或R 4独立地与其共价键合形成含氮杂环; R 7是H,(C 1-6烷基),(C 3-7)环烷基或(C 1-6)烷基 - (C 3-7)环烷基; 或R 7共价键合到R 3或R 4中的任一个以形成杂环; A是(C 1-6)烷基-CONHR 8,其中R 8是6-或10-元芳基,或Het; 或A是6-或10-元芳基,或Het表示芳基或Het任选被取代; 或其盐或衍生物; 这些化合物是HCV NS5B聚合酶的有效抑制剂。
    • 10. 发明授权
    • Viral polymerase inhibitors
    • US06448281B1
    • 2002-09-10
    • US09898297
    • 2001-07-03
    • Pierre Louis BeaulieuGulrez FazalJames GillardGeorge KukoljVolkhard Austel
    • Pierre Louis BeaulieuGulrez FazalJames GillardGeorge KukoljVolkhard Austel
    • A81K314184
    • C07D401/04C07D235/18C07D403/12C07D405/04C07D405/14C07D409/04C07D417/14C07D471/04Y10S514/894
    • A compound of the formula I: wherein: X is CH or N; Y is O or S; Z is OH, NH2, NMeR3, NHR3; OR3 or 5- or 6-membered heterocycle, having 1 to 4 heteroatoms selected from O, N and S, said heterocycle being optionally substituted with from 1 to 4 substituents; A is N, COR7 or CR5, wherein R5 is H, halogen, or (C1-6) alkyl and R7 is H or (C1-6 alkyl), with the proviso that X and A are not both N; R6 is H, halogen, (C1-6 alkyl) or OR7, wherein R7 is H or (C1-6 alkyl); R1 is selected from the group consisting of 5- or 6-membered heterocycle having 1 to 4 heteroatoms selected from O, N, and S, phenyl, phenyl(C1-3)alkyl, (C2-6)alkenyl, phenyl(C2-6)alkenyl, (C3-6)cycloalkyl, (C1-6)alkyl, CF3, 9- or 10-membered heterobicycle having 1 to 4 heteroatoms selected from O, N and S, wherein said heterocycle, phenyl, phenyl(C2-6)alkenyl and phenyl(C1-3)alkyl), alkenyl, cycloalkyl, (C1-6)alkyl, and heterobicycle are all optionally substituted with from 1 to 4 substituents; R2 is selected from (C1-6)alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C1-3)alkyl, (C6-10)bicycloalkyl, adamantyl, phenyl, and pyridyl, all of which is optionally substituted with from 1 to 4 substituents; R3 is selected from H, (C1-6)alkyl, (C3-6)cycloalkyl, (C3-6)cycloalkyl(C1-6)alkyl, (C6-10)aryl, (C6-10)aryl(C1-6)alkyl, (C2-6)alkenyl, (C3-6)cycloalkyl(C2-6)alkenyl, (C6-10)aryl(C2-6)alkenyl, N{(C1-6) alkyl}2, NHCOO(C1-6)alkyl(C6-10)aryl, NHCO(C6-10)aryl, (C1-6)alkyl-5- or 10-atom heterocycle, having 1 to 4 heteroatoms selected from O, N and S, and 5- or 10-atom heterocycle having 1 to 4 heteroatoms selected from O, N and S; wherein said alkyl, cycloalkyl, aryl, alkenyl and heterocycle are all optionally substituted with from 1 to 4 substituents; n is zero or 1; or a detectable derivative or salt thereof. The compounds of the invention may be used as inhibitors of hepatitis C virus replication. The invention further provides a method for treating or preventing hepatitis C virus infection.